These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

164 related articles for article (PubMed ID: 38756661)

  • 1. Predictive value of PD-L1 and TMB for short-term efficacy prognosis in non-small cell lung cancer and construction of prediction models.
    Shi S; Wang Y; Wu J; Zha B; Li P; Liu Y; Yang Y; Kong J; Gao S; Cui H; Huangfu L; Sun X; Li Z; Liang T; Zheng Y; Yang D
    Front Oncol; 2024; 14():1342262. PubMed ID: 38756661
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Association of Survival and Immune-Related Biomarkers With Immunotherapy in Patients With Non-Small Cell Lung Cancer: A Meta-analysis and Individual Patient-Level Analysis.
    Yu Y; Zeng D; Ou Q; Liu S; Li A; Chen Y; Lin D; Gao Q; Zhou H; Liao W; Yao H
    JAMA Netw Open; 2019 Jul; 2(7):e196879. PubMed ID: 31290993
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Construction of A Nomogram Prediction Model for PD-L1 Expression 
in Non-small Cell Lung Cancer Based on 18F-FDG PET/CT Metabolic Parameters].
    Hao L; Wang L; Zhang M; Yan J; Zhang F
    Zhongguo Fei Ai Za Zhi; 2023 Nov; 26(11):833-842. PubMed ID: 38061885
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Radiomics Study for Predicting the Expression of PD-L1 and Tumor Mutation Burden in Non-Small Cell Lung Cancer Based on CT Images and Clinicopathological Features.
    Wen Q; Yang Z; Dai H; Feng A; Li Q
    Front Oncol; 2021; 11():620246. PubMed ID: 34422625
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Real-world study on the efficacy and prognostic predictive biomarker of patients with metastatic non-small cell lung cancer treated with programmed death-1/programmed death ligand 1 inhibitors].
    Zhu WJ; Zhu HH; Liu YT; Lin L; Xing PY; Hao XZ; Cong MH; Wang HY; Wang Y; Li JL; Feng Y; Hu XS
    Zhonghua Zhong Liu Za Zhi; 2022 May; 44(5):416-424. PubMed ID: 35615798
    [No Abstract]   [Full Text] [Related]  

  • 6. Predictive value of spectral dual-detector computed tomography for
    Wang T; Fan Z; Yue Y; Lu X; Deng X; Hou Y
    Quant Imaging Med Surg; 2024 Aug; 14(8):5983-6001. PubMed ID: 39144026
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Predictive Value of Combining Biomarkers for Clinical Outcomes in Advanced Non-Small Cell Lung Cancer Patients Receiving Immune Checkpoint Inhibitors.
    Kao C; Powers E; Wu Y; Datto MB; Green MF; Strickler JH; Ready NE; Zhang T; Clarke JM
    Clin Lung Cancer; 2021 Nov; 22(6):500-509. PubMed ID: 33972172
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Integration of comprehensive genomic profiling, tumor mutational burden, and PD-L1 expression to identify novel biomarkers of immunotherapy in non-small cell lung cancer.
    Shi Y; Lei Y; Liu L; Zhang S; Wang W; Zhao J; Zhao S; Dong X; Yao M; Wang K; Zhou Q
    Cancer Med; 2021 Apr; 10(7):2216-2231. PubMed ID: 33655698
    [TBL] [Abstract][Full Text] [Related]  

  • 9. HLA-corrected tumor mutation burden and homologous recombination deficiency for the prediction of response to PD-(L)1 blockade in advanced non-small-cell lung cancer patients.
    Shim JH; Kim HS; Cha H; Kim S; Kim TM; Anagnostou V; Choi YL; Jung HA; Sun JM; Ahn JS; Ahn MJ; Park K; Park WY; Lee SH
    Ann Oncol; 2020 Jul; 31(7):902-911. PubMed ID: 32320754
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Robust Prediction of Immune Checkpoint Inhibition Therapy for Non-Small Cell Lung Cancer.
    Jiang J; Jin Z; Zhang Y; Peng L; Zhang Y; Zhu Z; Wang Y; Tong D; Yang Y; Wang J; Yang Y; Xiao K
    Front Immunol; 2021; 12():646874. PubMed ID: 33927719
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The clinical utility of tumor mutational burden in non-small cell lung cancer.
    Greillier L; Tomasini P; Barlesi F
    Transl Lung Cancer Res; 2018 Dec; 7(6):639-646. PubMed ID: 30505708
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Genomic scoring to determine clinical benefit of immunotherapy by targeted sequencing.
    Kim HS; Cha H; Kim J; Park WY; Choi YL; Sun JM; Ahn JS; Ahn MJ; Park K; Lee SH
    Eur J Cancer; 2019 Oct; 120():65-74. PubMed ID: 31493723
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Predictive Value of Lymphocyte-to-Neutrophil Ratio and Platelet-to-Neutrophil Ratio on PD-L1 Expression in Lung Cancer.
    Cui SS; Shen Y; Yang RQ
    Clin Respir J; 2024 Aug; 18(8):e13821. PubMed ID: 39140242
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Molecular Determinants of Response to Anti-Programmed Cell Death (PD)-1 and Anti-Programmed Death-Ligand 1 (PD-L1) Blockade in Patients With Non-Small-Cell Lung Cancer Profiled With Targeted Next-Generation Sequencing.
    Rizvi H; Sanchez-Vega F; La K; Chatila W; Jonsson P; Halpenny D; Plodkowski A; Long N; Sauter JL; Rekhtman N; Hollmann T; Schalper KA; Gainor JF; Shen R; Ni A; Arbour KC; Merghoub T; Wolchok J; Snyder A; Chaft JE; Kris MG; Rudin CM; Socci ND; Berger MF; Taylor BS; Zehir A; Solit DB; Arcila ME; Ladanyi M; Riely GJ; Schultz N; Hellmann MD
    J Clin Oncol; 2018 Mar; 36(7):633-641. PubMed ID: 29337640
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Prediction performance comparison of biomarkers for response to immune checkpoint inhibitors in advanced non-small cell lung cancer.
    Zhao J; Zhuang W; Sun B; Bai H; Wang Z; Zhong J; Wan R; Liu L; Duan J; Wang J
    Thorac Cancer; 2024 May; 15(13):1050-1059. PubMed ID: 38528429
    [TBL] [Abstract][Full Text] [Related]  

  • 16. First-Line Nivolumab Plus Ipilimumab in Advanced Non-Small-Cell Lung Cancer (CheckMate 568): Outcomes by Programmed Death Ligand 1 and Tumor Mutational Burden as Biomarkers.
    Ready N; Hellmann MD; Awad MM; Otterson GA; Gutierrez M; Gainor JF; Borghaei H; Jolivet J; Horn L; Mates M; Brahmer J; Rabinowitz I; Reddy PS; Chesney J; Orcutt J; Spigel DR; Reck M; O'Byrne KJ; Paz-Ares L; Hu W; Zerba K; Li X; Lestini B; Geese WJ; Szustakowski JD; Green G; Chang H; Ramalingam SS
    J Clin Oncol; 2019 Apr; 37(12):992-1000. PubMed ID: 30785829
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Mutations Associated with No Durable Clinical Benefit to Immune Checkpoint Blockade in Non-S-Cell Lung Cancer.
    Zhu G; Ren D; Lei X; Shi R; Zhu S; Zhou N; Zu L; Mello RA; Chen J; Xu S
    Cancers (Basel); 2021 Mar; 13(6):. PubMed ID: 33808631
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Predictive biomarkers for PD-1/PD-L1 checkpoint inhibitor response in NSCLC: an analysis of clinical trial and real-world data.
    So WV; Dejardin D; Rossmann E; Charo J
    J Immunother Cancer; 2023 Feb; 11(2):. PubMed ID: 36822668
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Predictive values of genomic variation, tumor mutational burden, and PD-L1 expression in advanced lung squamous cell carcinoma treated with immunotherapy.
    Xu Y; Li H; Huang Z; Chen K; Yu X; Sheng J; Zhang HH; Fan Y
    Transl Lung Cancer Res; 2020 Dec; 9(6):2367-2379. PubMed ID: 33489799
    [TBL] [Abstract][Full Text] [Related]  

  • 20. PD-L1 Protein Expression Is Associated With Good Clinical Outcomes and Nomogram for Prediction of Disease Free Survival and Overall Survival in Breast Cancer Patients Received Neoadjuvant Chemotherapy.
    Chen L; Huang S; Liu Q; Kong X; Su Z; Zhu M; Fang Y; Zhang L; Li X; Wang J
    Front Immunol; 2022; 13():849468. PubMed ID: 35669769
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.